Events

We attended the Investigator Meeting for Novel Innovative Therapeutic Initiatives in San Francisco, which focused on the simplification of antiretroviral therapy (ART). The DAYBREAK clinical trials are designed to evaluate the administration of broadly neutralizing monoclonal antibodies (bNAbs) in combination with lenacapavir, delivered via long-acting injectables every six months, as a replacement for daily oral regimens. It is a privilege to provide our patient population with access to these cutting-edge therapeutic initiatives.

Dr. Jimena López Piñeiro, a research fellow at the Foundation, was awarded the ‘Dr. Jorge Corral’ Research Grant, presented annually through a competitive process by the Argentine Society of Infectious Diseases (SADI). This grant recognizes her project on the early detection of anal neoplasia in high-risk patients, a collaborative study that we will carry out alongside the Malbrán Institute and the Ramos Mejía, Muñiz, and Udaondo Hospitals.

The event reached a significant turnout with more than 90 registered participants, featuring various stakeholders from the clinical research sector, including the primary Principal Investigator (PI) groups from the Hospital, authorities from the Ministry of Health, the City Legislature, and the Municipal Physicians Association. Project management departments, as well as representatives from the pharmaceutical industry and several Contract Research Organizations (CROs), were also in attendance. This venue provided a professional forum for the exchange of expertise and the strategic advancement of clinical research activities. Program

We attended CROI, the traditional Conference on Retroviruses and Opportunistic Infections, held this year in Denver, USA. We participated in the presentation of results from the PURPOSE 2 and ARTISTRY studies, among other exchange activities with colleagues from around the world. We are proud to be part of these cutting-edge research and innovation initiatives. Follow-up from the PURPOSE study confirms the extraordinary efficacy of a medication administered subcutaneously every six months to prevent HIV acquisition in at-risk individuals. The ARTISTRY study—published in The Lancet in conjunction with its presentation at this conference—shows that a simplified one-tablet-a-day regimen facilitates treatment for people who had been on complex regimens due to long-term infection (over 25 years) and exposure to multiple treatments. These long-acting drugs promise to revolutionize HIV prevention and treatment.

We received with great interest the visit from the PAHO Mission dedicated to monitoring the HIV, Hepatitis, STI, and Tuberculosis Infection Programs. During the working session our team held with specialists from PAHO, the National Ministry of Health, and the Ministry of Health of the GCBA, the work and experience of ClinSex were reviewed with great success.

Dr. Mariana A. Kundro attended IDWeek in Atlanta, GA, USA, where she was invited to chair the oral presentation session on Tuberculosis and Other Mycobacteria. Dr. Kundro also presented the results of the study on late diagnosis of HIV infection and the experience of ChemSex users; both works from the Emerging Diseases Section of the JM Ramos Mejía Hospital were accepted as posters.

Update Seminar: Challenges and Opportunities in the Development of Clinical Research. Organized in conjunction with the Clinical Research Course of the Faculty of Medicine (UBA) and the Innovation Unit of the Hospital Italiano de Buenos Aires, Prof. Emery’s Seminar was a true privilege for those who had the opportunity to discuss new development modalities and short- and medium-term perspectives.

We welcomed Luciana Kamel, Community Representative at the HVTN, who coordinates site activities in Argentina and Brazil. Luciana visited the Emerging Diseases Research Unit and met with members of our CAB. Thank you, Luciana, for your visit and your significant contributions!

A Dra. Mariana Kundro e o Dr. Guillermo Vilora compareceram à IDWeek em Boston, onde apresentaram dados da coorte de Mpox da ClinSex e os resultados sobre as experiências de implementação da telemedicina em vários hospitais públicos de Buenos Aires.